To see, to know, to heal .    

Declare the past,
diagnose the present,
foretell the future (Hippocrates)

Seeing is the

About us


The name photonamic consists of photo (= light) and dynamics and thus represents the field of activity of photonamic GmbH & Co. KG ("photonamic"). The effect of light on certain molecules is manifold and ultimately leads not only to coloration, but can also lead to fluorescence or initiation of chemical reactions.
Photonamic takes advantage of these dynamics of light by using a specific molecule that is metabolized into a photosensitizer in cells or in cell assemblies or in the body. Depending on the choice of wavelength, this can lead to a wide variety of effects triggered by the light. The use of light and the application of photosensitizers is not really a new principle, but has been known and researched for decades.
photonamic has set itself the goal of researching and developing these possibilities in a targeted manner in order to derive diverse applications from them. Unlike many other approaches, the molecule primarily used by photonamic is a precursor of the actual photosensitizer, which is metabolically converted into the light-excitable molecule and exhibits the corresponding photodyna-mic properties. The resulting fascinating applications in imaging and also therapy form the core of photonamic's activities.
Through numerous collaborations and projects with partner companies, academic institutions for clinical applicability and also with corresponding equipment companies for light sources, sensors and camera systems, the diversity of these technologies can be imagined.


‍"US FDA Medical Device Registration of Aladuck405/II"

SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director & President:Yoshitaka Kitao; hereinafter "SBIP"), a subsidiary company of SBI Holdings, Inc. which conductsresearch and development pharmaceuticals, etc., utilizing 5-aminolevulinic acid (*) announces todaythat the medical light source device "Aladuck405/II" (hereafter "Aladuck") marketed in Japan has beenregistered as a class II medical device with the U.S. FDA (Food and Drug Administration).

Prior to this, Aladuck has obtained "UL certification", one of the most recognized safety standards in the US electronics industry. In addition, Aladuck has obtained a conformity certificate "CB Report" byconducting safety tests on the device based on IEC (International Electrotechnical Commission) standards. These certifications have made it possible to obtain overseas certification easily andquickly.

Aladuck is a medical light source device that can be used in various surgical sites, as it can illuminate areas that are difficult to illuminate with conventional microscope light sources, and can be used together with a medical endoscope.SBIP will strive to fulfill Aladuck's worldwide needs and deliver them to wherever medical sites areneeded, both domestically and internationally.



All press articles